Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly EBT Margin came in at 283.75% in Q2 2026, down 14710.0% on a YoY basis from N/an in Q2 2025, and up 27.43% quarter-over-quarter from 390.98% in Q1 2026.
Powered by 
Analysis
Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has reported EBT Margin for 7 consecutive years, with 283.75% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 14710.0% year-over-year to 283.75%; the trailing twelve-month figure through Jun 2026 stood at 264.14% (down 12083.0% YoY), and the FY2025 full-year result was 184.3%, up 5684.0% from the prior year.
- EBT Margin advanced to 283.75% in Q2 2026 per DNA's latest filing, from 390.98% in the prior quarter.
- Across five years, EBT Margin topped out at 63.76% in Q3 2024 and bottomed at 1009.31% in Q3 2022.
- Historically, EBT Margin has averaged 318.47% across 5 years, with a median of 249.94% in 2023.
- The widest YoY moves for EBT Margin: up 89018 bps in 2022, down 87709 bps in 2022.
- Over 5 years, EBT Margin stood at 191.13% in 2022, then surged by 54 bps to 87.17% in 2023, then slumped by 182 bps to 245.99% in 2024, then advanced by 1 bps to 243.72% in 2025, then dropped by 16 bps to 283.75% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 283.75%, 390.98%, and 243.72% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 42.77 Bn | 40.69 Bn | 1.44 Bn | 6.89% |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 21.44% |
| 3 | Charles River Laboratories International | 13.37 Bn | 13.18 Bn | 452.07 Mn | 5.30% |
| 4 | Icon | 12.49 Bn | 11.56 Bn | 479.29 Mn | 4.47% |
| 5 | Fortrea Holdings | 1.58 Bn | 1.42 Bn | 139.20 Mn | -0.18% |
| 6 | Evotec SE | 642.83 Mn | 216.96 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 422.55 Mn | 338.02 Mn | 18.44 Mn | -283.75% |
| 8 | Champions Oncology | 69.16 Mn | 69.16 Mn | 7.03 Mn | -3.58% |
| 9 | MindWalk Holdings | 59.83 Mn | 51.55 Mn | 1.82 Mn | -105.20% |
| 10 | VivoSim Labs | 1.45 Mn | 1.45 Mn | - | -15,194.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -283.75% |
| Mar 31, 2026 | -390.98% |
| Dec 31, 2025 | -243.72% |
| Sep 30, 2025 | -207.93% |
| Jun 30, 2025 | -136.65% |
| Mar 31, 2025 | -217.69% |
| Dec 31, 2024 | -245.99% |
| Sep 30, 2024 | -63.76% |
| Jun 30, 2024 | -386.06% |
| Mar 31, 2024 | -437.17% |
| Dec 31, 2023 | -87.17% |
| Sep 30, 2023 | -546.48% |
| Jun 30, 2023 | -215.03% |
| Mar 31, 2023 | -253.88% |
| Dec 31, 2022 | -191.13% |
| Sep 30, 2022 | -1,009.31% |
| Jun 30, 2022 | -463.71% |
| Mar 31, 2022 | -351.99% |
| Dec 31, 2021 | -1,081.31% |
| Sep 30, 2021 | -132.21% |